✨ Onyx Summary Belite Bio entered an upsized PIPE financing led by RA Capital with participation from Eventide, Marshall Wace, RTW, Soleus, and Vestal Point, raising ~$125M upfront and issuing two-year warrants exercisable at a 20% premium ($76.80) for up to an additional ~$150M. The company will sell 1,
✨ Onyx Summary Adverum Biotechnologies granted inducement equity awards to two new employees, consisting of stock options to purchase 16,860 shares and 8,430 restricted stock units under its 2017 Inducement Plan. The awards, made in accordance with Nasdaq Listing Rule 5635(c)(4), align new hires’ incentives with shareholder
✨ Onyx Summary Lexicon Pharmaceuticals will present preclinical data at NeuPSIG 2025 showing pilavapadin (AAK1 inhibitor) reduced neuropathic pain in models of chemotherapy-induced peripheral neuropathy and multiple sclerosis, with a separate poster on the Phase 2b PROGRESS study design. The update broadens pilavapadin’s potential beyond diabetic peripheral neuropathic pain,
✨ Onyx Summary Perspective Therapeutics has appointed Joel Sendek as Chief Financial Officer, effective immediately. Sendek, a veteran biotech finance executive with over $2.5 billion raised across prior CFO roles and a top-ranked equity research background, succeeds Juan Graham and is expected to strengthen the company’s financial and
✨ Onyx Summary Lexicon Pharmaceuticals will present patient-reported outcomes on the impact of diabetic peripheral neuropathic pain at PAINWeek 2025 (Poster #53, Sept. 4, 4:00–5:30 p.m. PT, Las Vegas) led by Belinda Hardin, PharmD, BCPS, and Suma Gopinathan, Ph.D. The findings are intended to inform
✨ Onyx Summary ✨ Onyx Summary enGene Holdings announced it has reached target enrollment of 100 patients in the pivotal cohort of its Phase 2 LEGEND trial evaluating detalimogene voraplasmid in high-risk, BCG-unresponsive non-muscle invasive bladder cancer. The company plans to overenroll the cohort and now anticipates submitting a
✨ Onyx Summary Perspective Therapeutics has appointed Maya Martinez-Davis, President of GSK’s U.S. Commercial business, to its Board of Directors as an independent director. Martinez-Davis brings over two decades of biopharma leadership across GSK, Merck KGaA, and Pfizer, strengthening the company’s strategic and commercial expertise as
✨ Onyx Summary Allucent expanded its executive team, appointing Patrick Phillips as COO, Rachel Page as CCO, and Nate Thompson as CIO to strengthen operations, commercial execution, and technology/AI strategy. The hires aim to scale delivery for small and mid-sized biopharma clients, accelerating program execution and reinforcing Allucent’s
✨ Onyx Summary Lexicon reported a pooled post-hoc analysis of the SCORED and SOLOIST-WHF trials presented at ESC 2025 showing sotagliflozin reduced total CV death and HF events and lowered total MACE versus placebo consistently across age, including ≥65 and ≥75 years. The dataset (~12,000 participants; median age
✨ Onyx Summary Seer, Inc. appointed Isaac Ro, Partner at Catalio Capital Management, to its Board of Directors, adding extensive financial and sector expertise in life science tools and diagnostics. Ro’s background in leading high-growth companies through IPOs, acquisitions, and strategic scaling strengthens Seer’s governance as it advances
✨ Onyx Summary Keros Therapeutics announced that CEO Jasbir S. Seehra, Ph.D., will present at the Wells Fargo Healthcare Conference on September 4 and the H.C. Wainwright Global Investment Conference on September 9, 2025. The company will provide corporate and program updates, with presentation replays available for 90 days
✨ Onyx Summary Rocket Pharmaceuticals (NASDAQ: RCKT) will present at the Cantor Fitzgerald and Morgan Stanley Global Healthcare Conferences this September, spotlighting its late-stage genetic therapy pipeline for rare cardiovascular and hematologic disorders. With pivotal programs nearing key milestones, Rocket’s presence underscores its transition toward commercialization—an inflection point
✨ Onyx Summary Kyverna Therapeutics hosted a virtual KOL event outlining progress in its neuroimmunology CAR T franchise, including updated compassionate use data and details of its FDA-aligned Phase 3 trial design for KYV-101 in myasthenia gravis. The registrational KYSA-6 study, enrolling by year-end 2025, will evaluate
✨ Onyx Summary Lexicon Pharmaceuticals announced that management will participate in fireside chats at Citi’s Biopharma Back to School Conference on September 3, 2025, and the H.C. Wainwright Global Investment Conference on September 8, 2025, with live webcasts available on the company’s investor site. The events provide Lexicon
✨ Onyx Summary Recursion Pharmaceuticals announced participation in two upcoming investor conferences: the Citi 2025 BioPharma Back to School Conference on September 3, 2025, and the Morgan Stanley 23rd Annual Global Healthcare Conference on September 8, 2025. The company’s engagement underscores its strategy to highlight progress in scaling its Recursion
✨ Onyx Summary Belite Bio announced that its executive team will present at three major upcoming investor conferences in early September, including Cantor, Morgan Stanley, and H.C. Wainwright. Each presentation will be webcast and available for replay on the company’s investor relations website. These appearances highlight growing investor interest
